The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …

Chronic myeloid leukaemia (CML) is a myeloproliferative disorder arising in the
haemopoietic stem cell (HSC) compartment. This disease is characterised by a reciprocal t …

The introduction of selective tyrosine-kinase inhibitors (TKIs) for the treatment of chronic
myeloid leukaemia has changed patient outcome and, consequently, management of this …

Intrinsic sensitivity of newly diagnosed chronic myeloid leukemia (CML) patients to imatinib
(IC50imatinib) correlates with molecular response. IC50imatinib is defined as the in vitro …

The most common breakpoint cluster region gene-Abelson murine leukemia viral oncogene
homolog 1 (BCR-ABL) transcripts in chronic myeloid leukemia (CML) are e13a2 (b2a2) and …

The therapeutic armamentarium for chronic myeloid leukaemia (CML) comprises mainly
tyrosine kinase inhibitors (TKIs), with several agents available for frontline treatment, or for …

Interpatient variability in intracellular uptake and retention (IUR) of imatinib may be due to
variable function of the OCT-1 influx pump. OCT-1 activity was measured in pretherapy …

Although it is now generally accepted that imatinib is the best initial treatment for patients
newly diagnosed with chronic myeloid leukemia (CML) in chronic phase, a number of …

Tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukaemia (CML) is the
consummate success story for targeted therapy, yet relapse is a nearly inevitable …

Purpose: The organic cation transporter OCT-1 mediates active transport of imatinib. We
recently showed that low OCT-1 activity is a major contributor to suboptimal response in …